Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) EBITDA Margin: 2014-2025

Historic EBITDA Margin for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -173.51%.

  • ImmunityBio's EBITDA Margin rose 114082.00% to -173.51% in Q3 2025 from the same period last year, while for Sep 2025 it was -315.84%, marking a year-over-year increase of 459647.00%. This contributed to the annual value of -2,334.23% for FY2024, which is 5590532.00% up from last year.
  • As of Q3 2025, ImmunityBio's EBITDA Margin stood at -173.51%, which was up 35.68% from -269.76% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's EBITDA Margin registered a high of -173.51% during Q3 2025, and its lowest value of -685,514.29% during Q1 2022.
  • Over the past 3 years, ImmunityBio's median EBITDA Margin value was -9,487.39% (recorded in 2024), while the average stood at -58,942.45%.
  • As far as peak fluctuations go, ImmunityBio's EBITDA Margin plummeted by 62,345,385bps in 2022, and later spiked by 65,451,984bps in 2023.
  • Over the past 5 years, ImmunityBio's EBITDA Margin (Quarterly) stood at -20,326.67% in 2021, then tumbled by 9,597,470bps to -116,301.37% in 2022, then skyrocketed by 5,487,043bps to -61,430.94% in 2023, then soared by 6,051,197bps to -918.96% in 2024, then soared by 114,082bps to -173.51% in 2025.
  • Its EBITDA Margin stands at -173.51% for Q3 2025, versus -269.76% for Q2 2025 and -390.08% for Q1 2025.